PL377896A1 - Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu - Google Patents
Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianuInfo
- Publication number
- PL377896A1 PL377896A1 PL377896A PL37789604A PL377896A1 PL 377896 A1 PL377896 A1 PL 377896A1 PL 377896 A PL377896 A PL 377896A PL 37789604 A PL37789604 A PL 37789604A PL 377896 A1 PL377896 A1 PL 377896A1
- Authority
- PL
- Poland
- Prior art keywords
- methods
- modulatory compounds
- glutamate transport
- protein expression
- eaat
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
- 229930195712 glutamate Natural products 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000037087 Excitatory amino acid transporters Human genes 0.000 abstract 2
- 108091006291 Excitatory amino acid transporters Proteins 0.000 abstract 2
- 102000018725 Glutamate Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010091978 Glutamate Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45022703P | 2003-02-26 | 2003-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL377896A1 true PL377896A1 (pl) | 2006-02-20 |
Family
ID=32927622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL377896A PL377896A1 (pl) | 2003-02-26 | 2004-02-25 | Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060121488A1 (pl) |
| EP (1) | EP1611238B1 (pl) |
| JP (1) | JP2006524637A (pl) |
| KR (1) | KR20050115245A (pl) |
| AT (1) | ATE433993T1 (pl) |
| AU (1) | AU2004214938B2 (pl) |
| CA (1) | CA2516619A1 (pl) |
| DE (1) | DE602004021574D1 (pl) |
| DK (1) | DK1611238T3 (pl) |
| ES (1) | ES2328811T3 (pl) |
| MX (1) | MXPA05009134A (pl) |
| PL (1) | PL377896A1 (pl) |
| WO (1) | WO2004076675A2 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005398A (es) | 2002-11-22 | 2006-03-09 | Univ Johns Hopkins | Meta para terapia de deterioro cognitivo. |
| AU2004285473A1 (en) * | 2003-10-21 | 2005-05-12 | Johns Hopkins University | Neuroprotection with beta-lactam compounds |
| JP2008536808A (ja) * | 2005-03-04 | 2008-09-11 | アルスジエン・インコーポレーテツド | プロゲステロン受容体による神経変性疾患の調節 |
| ES2819303T3 (es) | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| WO2007098047A2 (en) * | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
| FR2902010B1 (fr) * | 2006-06-12 | 2008-08-22 | Pierre Fabre Medicament Sa | Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique |
| WO2009033055A1 (en) * | 2007-09-06 | 2009-03-12 | Rutgers, The State University Of New Jersey | Methods and kits for identification of anti-excitotoxic compounds |
| US20110201668A1 (en) * | 2008-01-30 | 2011-08-18 | Korea Institute Of Science And Technology | Regulation of neurotransmitter release through anion channels |
| EP2535059A4 (en) * | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF) |
| FR2958664B1 (fr) | 2010-04-07 | 2012-10-26 | Coatex Sas | Utilisation d'un latex de styrene et de taille de 100 nm comme agent rheologique dans une sauce de couchage papetiere, sauce et son procede d'obtention |
| US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| WO2012075408A1 (en) * | 2010-12-02 | 2012-06-07 | Massachusetts Institute Of Technology | Chemical and rnai suppressors of neurotoxicity in huntington's disease |
| EP2919816B1 (en) * | 2012-11-14 | 2019-03-27 | Daniel Offen | Combination treatment for amyotrophic lateral sclerosis (als) |
| US10448861B2 (en) * | 2013-09-06 | 2019-10-22 | Covidien Lp | System and method for light based lung visualization |
| CN104074095A (zh) * | 2014-06-25 | 2014-10-01 | 宁波天源科技有限公司 | 流变改质剂 |
| KR101809379B1 (ko) * | 2016-10-13 | 2017-12-14 | 연세대학교 산학협력단 | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| CN111116374B (zh) * | 2019-12-04 | 2020-12-15 | 北京理工大学 | 一种氨鲁米特与2-硝基苯甲酸合成π-π键共晶体的方法 |
| CN110923148B (zh) * | 2019-12-11 | 2021-05-14 | 华北制药股份有限公司 | 青霉素v钾高产菌及其在发酵生产青霉素v钾中的应用 |
| CN117482234B (zh) * | 2023-11-03 | 2026-07-14 | 赣南师范大学 | 促进Per基因和/或Slc1a基因表达的产品在制备治疗睡眠剥夺的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575506A (en) * | 1983-11-03 | 1986-03-11 | Zambon S.P.A. | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics |
| US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| CA2087449A1 (en) * | 1990-08-13 | 1992-02-14 | Joseph L. Roba | Use of heterocyclic amino-alcohol compounds for treatment of cns diseases |
| US5658782A (en) * | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
| US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
| US6255467B1 (en) * | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
| US7060457B2 (en) * | 1998-03-18 | 2006-06-13 | Johns Hopkins University | Aberrant glutamate transporters and methods of use |
| WO1999059964A1 (en) * | 1998-05-15 | 1999-11-25 | University Of Vermont | Novel analogs of 16-hydroxyeicosatetraenoic acid |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| WO2001012171A2 (en) * | 1999-08-16 | 2001-02-22 | Revaax Pharmaceuticals, Llc | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| US6248360B1 (en) * | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
| AU2001288792A1 (en) * | 2000-09-06 | 2002-03-22 | Neurotherapeutics, Llc | Method of treating neurologic disorders |
| US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
| US7723505B2 (en) * | 2002-02-15 | 2010-05-25 | The John Hopkins University | EAAT2 promoter and uses thereof |
| MXPA05005398A (es) * | 2002-11-22 | 2006-03-09 | Univ Johns Hopkins | Meta para terapia de deterioro cognitivo. |
-
2004
- 2004-02-25 EP EP04714617A patent/EP1611238B1/en not_active Expired - Lifetime
- 2004-02-25 KR KR1020057015591A patent/KR20050115245A/ko not_active Withdrawn
- 2004-02-25 MX MXPA05009134A patent/MXPA05009134A/es active IP Right Grant
- 2004-02-25 WO PCT/US2004/005698 patent/WO2004076675A2/en not_active Ceased
- 2004-02-25 JP JP2006503879A patent/JP2006524637A/ja active Pending
- 2004-02-25 AU AU2004214938A patent/AU2004214938B2/en not_active Ceased
- 2004-02-25 DE DE602004021574T patent/DE602004021574D1/de not_active Expired - Lifetime
- 2004-02-25 ES ES04714617T patent/ES2328811T3/es not_active Expired - Lifetime
- 2004-02-25 DK DK04714617T patent/DK1611238T3/da active
- 2004-02-25 CA CA002516619A patent/CA2516619A1/en not_active Abandoned
- 2004-02-25 US US10/546,860 patent/US20060121488A1/en not_active Abandoned
- 2004-02-25 PL PL377896A patent/PL377896A1/pl not_active Application Discontinuation
- 2004-02-25 AT AT04714617T patent/ATE433993T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004214938B2 (en) | 2008-11-06 |
| EP1611238A4 (en) | 2007-07-04 |
| EP1611238A2 (en) | 2006-01-04 |
| EP1611238B1 (en) | 2009-06-17 |
| AU2004214938A1 (en) | 2004-09-10 |
| MXPA05009134A (es) | 2005-12-05 |
| JP2006524637A (ja) | 2006-11-02 |
| DK1611238T3 (da) | 2009-10-26 |
| ATE433993T1 (de) | 2009-07-15 |
| KR20050115245A (ko) | 2005-12-07 |
| WO2004076675A3 (en) | 2005-03-17 |
| CA2516619A1 (en) | 2004-09-10 |
| ES2328811T3 (es) | 2009-11-18 |
| DE602004021574D1 (de) | 2009-07-30 |
| US20060121488A1 (en) | 2006-06-08 |
| WO2004076675A2 (en) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1611238T3 (da) | Modulatoriske glutamattransportforbindelser og -fremgangsmåder | |
| ATE486087T1 (de) | Fgf-5-bindende und geträgerte peptide | |
| BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| IL191374A0 (en) | Methods for the treatment of muscle loss | |
| GB9911047D0 (en) | Assay method and means | |
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2003089456A3 (en) | Peptide inhibitors of protein kinase c | |
| BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
| EA201490735A1 (ru) | Лечение дегенеративного заболевания сустава | |
| WO2003011898A3 (fr) | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations | |
| WO2007087131A3 (en) | Peptide prodrugs | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| WO2007053390A3 (en) | Methods for the use of branched chain amino acids | |
| MY151330A (en) | Systems and method for separating proteins from connective tissue | |
| ES2507094T3 (es) | Proteína específica del timo | |
| CY1110381T1 (el) | Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων | |
| ZA202304030B (en) | Modified cxcl10 for immunotherapy of cancer diseases | |
| WO2002052270A3 (en) | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases | |
| NO20051159L (no) | Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| AR128224A1 (es) | Compuestos y métodos para tratar la ataxia de friedreich | |
| WO2004042035A3 (en) | Organic anion transport polypeptide related protein-4 (oatprp4) gene in tourette syndrome and related disorders | |
| WO2004018700A3 (en) | Method of modulating and of identifying agents that modulate intracellular calcium | |
| WO2004047612A3 (en) | Methods of therapy and diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |